Multiple Sclerosis Discovery Forum
  News and Future Directions
  Papers
  Forums
  Professional Resources
  Research Resources
MSGene - Gene overview of all published MS-association studies for IL7R
Back Search Methods Disclaimer Credits
 Gene: IL7R  (ILRA; IL7R; IL-7R-alpha; CDW127; IL7RA; CD127)  Entrez Gene
 Protein: interleukin 7 receptor   ProteinLink
 Chromosome: 5   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 25 November 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      MS Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result
 Caucasian
Akkad, 2009
 Germany CL  5  (detail)  1319
(68%)		P31.6
(-)		-908
(47%)		46.7
(-)		Positive
Alcina, 2008
 Spain CL  1  (detail)  599
(-)		P--594
(-)		-Positive
ANZgene, 2009
 Overlaps with
IMSGC, 2008 (Australia, New Zealand, USA, UK)		 CL,PO  2  (detail)  1618
(72%)		O/M34.1
(7-67)		-3413
(-)		-n.a.
ANZgene, 2009
 Australia, New Zealand (REP) CL  2  (detail)  2256
(78%)		O/M34.5
(4-73)		-2310
(-)		-Negative
Aulchenko, 2008
 Netherlands (GWAS) CL  2  (detail)  45
(-)		O/M--195
(-)		-Negative
Ban, 2009
 Overlaps with
IMSGC, 2008 (Belgium)		 CL  1  (detail)  368
(-)		O/M--374
(-)		-n.a.
Ban, 2009
 Overlaps with
IMSGC, 2008 (Norway)		 CL  1  (detail)  638
(-)		O/M32
(-)		46.3
(-)		1026
(-)		-n.a.
Ban, 2009
 Overlaps with
Gregory, 2007 (UK)		 CL  1  (detail)  475
(-)		O/M--479
(-)		-n.a.
Ban, 2009
 Overlaps with
IMSGC, 2008 (USA)		 CL  1  (detail)  1222
(-)		O/M--543
(-)		-n.a.
Ban, 2009
 Overlaps with
IMSGC, 2008 (UK)		 CL  1  (detail)  1531
(-)		O/M31
(-)		44
(-)		561
(-)		-n.a.
Baranzini, 2008
 USA, Netherlands, Switzerland (GWAS) CL  5  (detail)  978
(67%)		MD1&234
(11-61)		47
(21-69)		883
(66%)		46
(21-69)		Negative
Booth, 2005
 Australia CL  1  (detail)  363
(-)		O/M--182
(-)		-Positive
Broux, 2010
 Belgium CL  4  (detail)  65
(-)		U34.4
(-)		44.7 + 11.2
(20-68)		33
(-)		33.2 + 10.7
(21-55)		Negative
D'Netto, 2009
 Canada CL  1  (detail)  43
(-)		U--182
(-)		-Negative
Gregory, 2007
 Overlaps with
IMSGC, 2008 (UK, Belgium)		 CL  1  (detail)  1077
(69%)		U33.6
(10-62)		50
(-)		2725
(50%)		44.6
(24-61)		Positive
Gregory, 2007
 Overlaps with
IMSGC, 2008 (USA)		 CL  7  (detail)  438
(68%)		U31.9
(11-60)		41.8
(-)		479
(66%)		41.6
(21-60)		Positive
Hoe, 2010
 Australia (Westmead) CL  4  (detail)  810
(-)		U--991
(-)		-Positive
Hoppenbrouwers, 2008
 Overlaps with
Hoppenbrouwers, 2009		 CL  1  (detail)  46
(72%)		P33 + 11
(-)		-194
(-)		-n.a.
Hoppenbrouwers, 2009
 Netherlands (isolated) CL  1  (detail)  45
(-)		O/M--195
(-)		-Negative
Hoppenbrouwers, 2009
 Netherlands (outbred) CL  1  (detail)  490
(-)		O/M--426
(-)		-Negative
IMSGC, 2007
 Overlaps with
IMSGC, 2008 (UK)		 CL  1  (detail)  928
(73%)		MD1&232.6
(13-60)		45.1
(17-79)		1475
(-)		-n.a.
IMSGC, 2007
 Overlaps with
IMSGC, 2008 (USA, UK)		 CL,PO  3  (detail)  931
(75%)		MD1&227.8
(10-51)		38.6
(17-59)		2431
(-)		-n.a.
IMSGC, 2007
 Overlaps with
IMSGC, 2008 (USA)		 CL  1  (detail)  1394
(73%)		MD1&233.1
(3-69)		45.4
(18-74)		1512
(-)		-n.a.
IMSGC, 2008
 Overlaps with
Lundmark, 2007 (Sweden)		 CL  1  (detail)  1100
(-)		U--1251
(-)		-n.a.
IMSGC, 2008
 Overlaps with
Kallio, 2009 (Finland)		 CL  1  (detail)  561
(-)		U--1017
(-)		-n.a.
IMSGC, 2008
 UK CL  1  (detail)  2323
(-)		U--2960
(-)		-Positive
IMSGC, 2008
 USA CL  1  (detail)  1394
(-)		U--2466
(-)		-Positive
IMSGC, 2008
 Denmark CL  1  (detail)  504
(-)		U--541
(-)		-Positive
IMSGC, 2008
 Overlaps with
ANZgene, 2009 (Australia)		 CL  1  (detail)  472
(-)		U--424
(-)		-n.a.
IMSGC, 2008
 Belgium CL  1  (detail)  405
(-)		U--462
(-)		-Positive
IMSGC, 2008
 Germany CL  1  (detail)  206
(-)		U--605
(-)		-Negative
IMSGC, 2008
 Italy CL  1  (detail)  863
(-)		U--775
(-)		-Positive
IMSGC, 2008
 Overlaps with
Sanna, 2010		 CL  1  (detail)  909
(-)		U--576
(-)		-n.a.
IMSGC, 2008
 Overlaps with
Hoppenbrouwers, 2009 (Netherlands)		 CL  1  (detail)  46
(-)		U--194
(-)		-n.a.
IMSGC, 2008
 UK (Northern Ireland) CL  1  (detail)  683
(-)		U--532
(-)		-Negative
IMSGC, 2008
 Norway CL  1  (detail)  738
(-)		U--1027
(-)		-Positive
IMSGC, 2008
 Spain CL  1  (detail)  815
(-)		U--786
(-)		-Negative
Kallio, 2009
 Finland (isolate) PO  4  (detail)  197
(-)		O/M--433
(-)		-Positive
Kallio, 2009
 Overlaps with
Lundmark, 2007 (Sweden)		 CL  4  (detail)  651
(-)		O/M--651
(-)		-n.a.
Kallio, 2009
 Finland (other) CL  4  (detail)  725
(-)		O/M--959
(-)		-Positive
Lundmark, 2007
 Sweden,Norway,Denmark,Finland CL  3  (detail)  1820
(72%)		O/M-46.4
(-)		2634
(53%)		38.6
(-)		Positive
Lundmark, 2007
 Sweden CL  11  (detail)  1210
(73%)		O/M--1234
(63%)		45.6
(-)		Positive
O'Doherty, 2008
 USA CL,PO  8  (detail)  208
(-)		U--413
(-)		-Positive
O'Doherty, 2008
 Overlaps with
IMSGC, 2008 (Northern Ireland)		 CL  8  (detail)  463
(-)		U--532
(-)		-Negative
Rubio, 2008
 Overlaps with
ANZgene, 2009 (GWAS)		 CL  1  (detail)  1146
(75%)		O/M32
(7-67)		-1309
(-)		-n.a.
Sanna, 2010
 Italy-Sardinia (GWAS) CL  1  (detail)  882
(-)		MD1--872
(-)		-Negative
Sombekke, 2011
 Overlaps with
Baranzini, 2008 (Netherlands)		 CL  1  (detail)  697
(64%)		O/M32.1
(-)		-174
(56%)		46.5
(-)		Positive
Stankovic, 2010
 Serbia CL  1  (detail)  375
(-)		O/M--227
(-)		-Negative
Stankovic, 2010
 Croatia CL  1  (detail)  161
(-)		O/M--261
(-)		-Negative
Stankovic, 2010
 Slovenia CL  1  (detail)  142
(-)		O/M--109
(-)		-Negative
Teutsch, 2003
 Overlaps with
Booth, 2005		 CL  3  (detail)  176
(-)		P--176
(-)		-Trend
Weber, 2008
 Overlaps with
IMSGC, 2008 (Germany)		 CL  1  (detail)  206
(63%)		O/M-37.8
(19-59)		605
(-)		-n.a.
WTCCC, 2007
 Overlaps with
IMSGC, 2008 (UK)		 CL,PO  4  (detail)  994
(72%)		O/M30.3
(10-60)		43.8
(17-79)		1466
(50%)		-Positive
Zhang, 2005
 Sweden CL  5  (detail)  672
(72%)		P31.5
(-)		45.6
(15-80)		672
(49%)		54.5
(17-91)		Positive
 African Descent
Johnson, 2009
 USA CL  1  (detail)  918
(79%)		MD1--656
(71%)		-Negative
 Other/Mixed
Heidari, 2010
 Iran CL  4  (detail)  100
(78%)		O/M28.8
(-)		-100
(68%)		-Positive
Pandit, 2010
 India CL  1  (detail)  197
(48%)		MD130 + 5.6
(-)		35.4 + 3.2
(-)		197
(49%)		31.2 + 4.4
(-)		Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result
 Caucasian
Ban, 2009
 Australia  1  (detail)  372-O/M32.9
(-)		47.2
(-)		--Negative
Ban, 2009
 USA  1  (detail)  875-O/M----Positive
Ban, 2009
 Overlaps with
Gregory, 2007 (Belgium)		  1  (detail)  113-O/M----n.a.
Ban, 2009
 Overlaps with
Gregory, 2007 (UK)		  1  (detail)  693-O/M----n.a.
Booth, 2005
 Australia  1  (detail)  216-O/M----Positive
D'Netto, 2009
 Overlaps with
D'Netto, 2009 (CC)		  1  (detail)  43211
(-)		U----n.a.
Gregory, 2007
 UK, Belgium  1  (detail)  13381338
(74%)		U27.1
(9-53)		37.9
(-)		2676
(50%)		-Positive
Gregory, 2007
 Overlaps with
Ban, 2009 (USA)		  14  (detail)  7601055
(74%)		U29.8
(3-63)		43.4
(-)		--Positive
Hoppenbrouwers, 2009
 Canada  1  (detail)   1318
(-)		O/M--1507
(-)		-Positive
IMSGC, 2007
 Overlaps with
Gregory, 2007 (UK)		  1  (detail)  380380
(75%)		MD1&227.4
(10-53)		37.4
(17-58)		--n.a.
IMSGC, 2007
 Overlaps with
IMSGC, 2008 (USA)		  1  (detail)  229229
(79%)		MD1&231.1
(9-51)		39.4
(19-58)		--n.a.
IMSGC, 2007
 Overlaps with
IMSGC, 2007 (UK-GWAS, CC)		  1  (detail)  453453
(75%)		MD1&226.5
(10-48)		38.2
(19-59)		--Positive
IMSGC, 2007
 Overlaps with
IMSGC, 2007 (USA-GWAS, CC)		  1  (detail)  478478
(74%)		MD1&229
(11-51)		39
(17-57)		--Positive
IMSGC, 2008
 Overlaps with
Gregory, 2007 (Belgium)		  1  (detail)  114-U----n.a.
IMSGC, 2008
 Overlaps with
Gregory, 2007 (UK)		  1  (detail)  833-U----n.a.
IMSGC, 2008
 Finland  1  (detail)  254-U----Negative
IMSGC, 2008
 Overlaps with
Ban, 2009 (USA)		  1  (detail)  707-U----n.a.
IMSGC, 2008
 France  1  (detail)  540-U----Negative
IMSGC, 2008
 Italy (Sardinia)  1  (detail)  363-U----Negative
Ramagopalan, 2009
 Overlaps with
Hoppenbrouwers, 2009		  1  (detail)  6001193
(-)		U--1553
(-)		-n.a.
Riise Stensland, 2005
 Finland  1  (detail)  444497
(-)		P----Negative
Teutsch, 2003
 Overlaps with
Booth, 2005		  1  (detail)  186-P----n.a.
Weber, 2008
 Overlaps with
IMSGC, 2008 (France)		  1  (detail)  540540
(70%)		O/M26.5
(9-47)		41.7
(19-67)		1080
(50%)		-n.a.
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine MS diagnosis ->  "P" (Poser criteria, 1983), "MD1" (McDonald criteria, 2001), "MD2" (revised McDonald criteria, 2005), "MD1&2" (McDonald criteria, 2001 and 2005), "O/M" (other/mixed), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
MSDF RSS

Text size
Share & Bookmark
MSGene Recent Updates
MSGene Top Results
Top Results Details
1. HLA-DRB1
2. IL2RA
3. IL7R
4. TAGAP
5. CLEC16A
6. EVI5
7. GWA_16q24.1
8. GWA_5p13.1
9. TTC34
10. AHI1   
[see more]
MSGene Stats
Studies: 789
Genes: 809
Polymorphisms: 2907
Meta-analyses: 324
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2024 Biomedical Research Forum LLC Disclaimer Copyright